Ocular surface damage by ophthalmic compounds

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 5, 2011, Pages 464-470

  Mantelli, Flavio ^a   Tranchina, Laura ^b   Lambiase, Alessandro ^a   Bonini, Stefano ^a  

^a UNIVERSITY OF ROME G MARCONI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

allergic conjunctivitis; dry eye; glaucoma; ocular toxicity; preservatives

Indexed keywords

BENZALKONIUM CHLORIDE; EYE DROPS; GALECTIN 3; KETOTIFEN; LEVOCABASTINE; OLOPATADINE;

ALLERGIC CONJUNCTIVITIS; APPLICATION SITE ECZEMA; CELL ACTIVATION; CHEMOSIS; CLINICAL FEATURE; CONJUNCTIVAL HYPEREMIA; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; DRY EYE; EPIPHORA; EYE ALLERGY; EYE INJURY; EYE TOXICITY; GLAUCOMA; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; KERATOCONJUNCTIVITIS SICCA; MEDICAL HISTORY; NONHUMAN; OCULAR PRURITUS; OCULAR SURFACE DAMAGE; PHOTOPHOBIA; PRIORITY JOURNAL; PUNCTATE KERATITIS; REVIEW; TEAR FILM; TREATMENT DURATION;

ADMINISTRATION, OPHTHALMIC; ANTI-ALLERGIC AGENTS; BIOLOGICAL MARKERS; DISEASE SUSCEPTIBILITY; DRUG HYPERSENSITIVITY; DRY EYE SYNDROMES; EPITHELIUM; EYE; EYE DISEASES; HUMANS; INFLAMMATION; MUCIN 5AC; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL;

EID: 80052491336     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32834a95c9     Document Type: Review

References (82)

1. Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging 2011; 28:267-282
2. Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010; 29:312-334
3. Granet D. Allergic rhinoconjunctivitis and differential diagnosis of the red eye. Allergy Asthma Proc 2008; 29:565-574
4. Novaes P, Saldiva PH, Matsuda M, et al. The effects of chronic exposure to traffic derived air pollution on the ocular surface. Environ Res 2010; 110:372-374
5. Novaes P, do Nascimento Saldiva PH, Kara-José N, et al. Ambient levels of air pollution induce goblet-cell hyperplasia in human conjunctival epithelium. Environ Health Perspect 2007; 115:1753-1756
6. Wirbelauer C. Management of the red eye for the primary care physician. Am J Med 2006; 119:302-306
7. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 2005; 5:459-463 (Pubitemid 41345317)
8. Rummenie VT, Matsumoto Y, Dogru M, et al. Tear cytokine and ocular surface alterations following brief passive cigarette smoke exposure. Cytokine 2008; 43:200-208
9. Ueta M, Kinoshita S. Ocular surface inflammation mediated by innate immunity. Eye Contact Lens 2010; 36:269-281
10. Tarabishy AB, Jeng BH. Bacterial conjunctivitis: a review for internists. Cleve Clin J Med 2008; 75:507-512
11. Sacchetti M, Lambiase A, Coassin M, et al. Toxic corneal ulcer: a frequent and sight-threatening disease. Eur J Ophthalmol 2009; 19:916-922
12. Mantelli F, Lambiase A, Bonini S. A simple and rapid diagnostic algorithm for the detection of ocular allergic diseases. Curr Opin Allergy Clin Immunol 2009; 9:471-476
13. Ayaki M, Iwasawa A, Inoue Y. Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells. Clin Ophthalmol 2010; 21:1217-1222
14. Ayaki M, Iwasawa A, Soda M, et al. Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. Clin Ophthalmol 2010; 4:1019-1024
15. Ayaki M, Iwasawa A. Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines. Clin Ophthalmol 2010; 4:919-924
16. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophtalmol 2010; 88:329-336
17. Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol 2010; 4:1-9
18. Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res 2011; 36:391-398
19. Lin Z, Lui X, Zhou T, et al. A mouse dry eye model induced by topical administration of benzalkonium chloride. Mol Vis 2011; 17:257-264
20. Ayaki M, Iwasawa A, Yaguchi S, Koide R. Preserved and unpreserved antiallergic ophthalmic solutions and ocular surface toxicity: in vitro assessment in four cultured corneal and conjunctival epithelial cell lines. Biocontrol Sci 2010; 15:143-148
21. Ayaki M, Iwasawa A, Yaguchi S, Koide R. In vitro assessment of the cytotoxicity of antiallergic eye drops using 5 cultured corneal and conjunctival cell lines. J Oleo Sci 2011; 60:139-144
22. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloridepreserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 2010; 27:837-845
23. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther 2006; 23: 663-671 (Pubitemid 44955845)
24. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004; 23:490-496 (Pubitemid 38857008)
25. Guenoun JM, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctivaderived epithelial cells. Invest Ophthalmol Vis Sci 2005; 46:2444-2450 (Pubitemid 43119492)
26. Becquet F, Goldschild M, Moldovan MS, et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res 1998; 17:419-425 (Pubitemid 28178417)
27. Trocme S, Hwang LJ, Bean GW, Sultan MB. The role of benzalkonium chloride in the occurrence of punctate keratitis: a meta-analysis of randomized, controlled clinical trials. Ann Pharmacother 2010; 44:1914-1921
28. Pisella PJ, Pouloquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86:418-423 (Pubitemid 34293291)
29. Jaenen N, Baudouin C, Poiliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341-349 (Pubitemid 47056287)
30. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology 1989; 96:327-335 (Pubitemid 19078905)
31. Manni G, Centofanti M, Oddone F, et al. Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservativefree nonselective beta-blockers. Am J Ophthalmol 2005; 139:72-77 (Pubitemid 40094842)
32. Broadway D, Hitchings R. Conjunctival damage induced by long-term topical antiglaucoma therapy. Acta Ophthalmol Scand 1996; 74:97
33. Brandt JD, Wittpenn JR, Katz LJ, et al. Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol 1991; 112:297-301
34. Arici MK, Arici DS, Topalkara A, Gü ler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exp Ophthalmol 2000; 28:113-117 (Pubitemid 30458440)
35. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005; 115:118-122 (Pubitemid 40075430)
36. Hong J, Bielory L. Allergy to ophthalmic preservatives. Curr Opin Allergy Clin Immunol 2009; 9:447-453
37. Baines MG, Cai F, Backman HA. Ocular hypersensitivity to thimerosal in rabbits. Invest Ophthalmol Vis Sci 1991; 32:2259-2265
38. Ciprandi G, Buscaglia S, Pesce GP, et al. Ocular challenge and hyperresponsiveness to histamine in patients with allergic conjunctivitis. J Allergy Clin Immunol 1993; 91:1227-1230 (Pubitemid 23173192)
39. Sullivan-Mee M, Pensyl D, Alldredge B, et al. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations. J Ocul Pharmacol Ther 2010; 26:355-360
40. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 2007; 5:75-92
41. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 2007; 5:93-107
42. Quigley HA. Glaucoma. Lancet 2011; 377:1367-1377
43. Leung E, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008; 17:350-355
44. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 2007; 5:163-178
45. Ceulemans J, Vinckier I, Ludwig A. The use of xanthan gum in an ophthalmic liquid dosage form: rheological characterization of the interaction with mucin. J Pharm Sci 2002; 91:1117-1127 (Pubitemid 34640936)
46. Paugh JR, Nguyen AL, Ketelson HA, et al. Precorneal residence time of artificial tears measured in dry eye subjects. Optom Vis Sci 2008; 85:725-731
47. Mantelli F, Argüeso P. Functions of ocular surface mucins in health and disease. Curr Opin Allergy Clin Immunol 2008; 8:477-483
48. Gipson IK, Hori Y, Argüeso P. Character of ocular surface mucins and their alteration in dry eye disease. Ocul Surf 2004; 2:131-148 (Pubitemid 41268494)
49. Paulsen F, Jäger K, Worlitzsch D, et al. Regulation of MUC16 by inflammatory mediators in ocular surface epithelial cell lines. Ann Anat 2008; 190:59-70 (Pubitemid 351168658)
50. Mantelli F, Schaffer L, Dana R, et al. Glycogene expression in conjunctiva of patients with dry eye: downregulation of Notch signaling. Invest Ophthalmol Vis Sci 2009; 50:2666-2672
51. Argüeso P, Balaram M, Spurr-Michaud S, et al. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome. Invest Ophthalmol Vis Sci 2002; 43:1004-1011 (Pubitemid 34258267)
52. Sumiyoshi M, Ricciuto J, Tisdale A, et al. Antiadhesive character of mucin O-glycans at the apical surface of corneal epithelial cells. Invest Ophthalmol Vis Sci 2008; 49:197-203
53. Chung SH, Lee SK, Cristol SM, et al. Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on precorneal mucin. Mol Vis 2006; 12:415-421
54. Argüeso P, Guzman-Aranguez A, Mantelli F, et al. Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier. J Biol Chem 2009; 284:23037-23045
55. Ramselaar JA, Boot JP, van Haeringen NJ, et al. Corneal epithelial permeability after instillation of ophthalmic solutions containing local anaesthetics and preservatives. Curr Eye Res 1988; 7:947-950
56. Dong JQ, Babusis DM, Welty DF, et al. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther 2004; 20:285-292 (Pubitemid 39108893)
57. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007; 16:98-103 (Pubitemid 46114782)
58. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:701-713 (Pubitemid 34620348)
59. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108:1943-1953 (Pubitemid 33032760)
60. Ammar DA, Kahook MY. The effects of combination glaucoma medications on ocular surface epithelial cells. Adv Ther 2009; 26:970-975
61. Charnock C. Are multidose over-the-counter artificial tears adequately preserved? Cornea 2006; 25:432-437 (Pubitemid 44620128)
62. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells. Adv Ther 2011; 28:501-510
63. Epstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther 2009; 25:113-119
64. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004; 45:1360-1368 (Pubitemid 38859312)
65. Kim CY, Hong S, Seong GJ. Brimonidine 0.2%versus brimonidine purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther 2007; 23:481-486 (Pubitemid 350202483)
66. Mundorf T, Wilcox KA, Ousler GW 3rd, et al. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv Ther 2003; 20:329-336 (Pubitemid 38332673)
67. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 2007; 48:4123-4128 (Pubitemid 351261038)
68. Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther 2008; 25:743-751
69. Lipener C; Contact Lens Advisory in Scientific Studies (CLASS) group. A randomized clinical comparison of OPTI-FREE EXPRESS and ReNu MultiPLUS multipurpose lens care solutions. Adv Ther 2009; 26:435-446
70. Labbé A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 2006; 22:267-278 (Pubitemid 44689667)
71. Manni G, Centofanti M, Sacchetti M, et al. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma 2004; 13:163-167 (Pubitemid 38372829)
72. Zimmerman TJ, Boger WP 3rd. The beta-adrenergic blocking agents and the treatment of glaucoma. Surv Ophthalmol 1979; 23:347-362 (Pubitemid 9199790)
73. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 2003; 12:486-490 (Pubitemid 37494177)
74. Astin M, Stjernschantz J, Selén G. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res 1994; 59:401-407
75. Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol 2002; 133:401-403 (Pubitemid 34171592)
76. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998; 105:263-268 (Pubitemid 28090830)
77. Nakashima M, Nakamura T, Teshima M, et al. Breakdown evaluation of corneal epithelial barrier caused by antiallergic eyedrops using an electrophysiologic method. J Ocul Pharmacol Ther 2008; 24:43-51 (Pubitemid 351156627)
78. Pauly A, Brignole-Baudouin F, Guenoun JM, et al. Comparative study of topical antiallergic eye drops on human conjunctiva-derived cells: responses to histamine and IFN gamma and toxicological profiles. Graefes Arch Clin Exp Ophthalmol 2007; 245:534-546 (Pubitemid 46477314)
79. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002; 42:1-11 (Pubitemid 34075973)
80. Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf 2002; 25:233-250 (Pubitemid 34569358)
81. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 2001; 108:936-944 (Pubitemid 32374251)
82. Flach AJ. Corneal melts associated with topically applied nonsteroidal antiinflammatory drugs. Trans Am Ophthalmol Soc 2001; 99:205-210